APA citiranje

Minegishi, Y., Yamaguchi, O., Sugawara, S., Kuyama, S., Watanabe, S., Usui, K., . . . Gemma, A. (2021). A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. BMC Cancer.

Citação norma Chicago

Minegishi, Yuji, et al. "A Phase II Study of First-line Afatinib for Patients Aged ≥75 Years With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer: North East Japan Study Group Trial NEJ027." BMC Cancer 2021.

MLA citiranje

Minegishi, Yuji, et al. "A Phase II Study of First-line Afatinib for Patients Aged ≥75 Years With EGFR Mutation-positive Advanced Non-small Cell Lung Cancer: North East Japan Study Group Trial NEJ027." BMC Cancer 2021.